HomeCompareDUKH vs PFE

DUKH vs PFE: Dividend Comparison 2026

DUKH yields 5.93% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DUKH wins by $16498.97M in total portfolio value
10 years
DUKH
DUKH
● Live price
5.93%
Share price
$23.93
Annual div
$1.42
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$16499.02M
Annual income
$15,981,461,627.54
Full DUKH calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — DUKH vs PFE

📍 DUKH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDUKHPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DUKH + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DUKH pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DUKH
Annual income on $10K today (after 15% tax)
$504.21/yr
After 10yr DRIP, annual income (after tax)
$13,584,242,383.41/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, DUKH beats the other by $13,584,220,063.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DUKH + PFE for your $10,000?

DUKH: 50%PFE: 50%
100% PFE50/50100% DUKH
Portfolio after 10yr
$8249.54M
Annual income
$7,990,743,943.13/yr
Blended yield
96.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

DUKH
No analyst data
Altman Z
0.4
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DUKH buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDUKHPFE
Forward yield5.93%6.13%
Annual dividend / share$1.42$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$16499.02M$49.6K
Annual income after 10y$15,981,461,627.54$26,258.71
Total dividends collected$16463.13M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DUKH vs PFE ($10,000, DRIP)

YearDUKH PortfolioDUKH Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,886$1,186.38$9,153$693.39+$2.7KDUKH
2$15,354$2,635.84$8,593$849.25+$6.8KDUKH
3$22,793$6,364.20$8,336$1,066.78+$14.5KDUKH
4$42,048$17,659.07$8,437$1,384.80+$33.6KDUKH
5$105,882$60,890.77$9,013$1,875.40+$96.9KDUKH
6$399,893$286,599.75$10,306$2,680.72+$389.6KDUKH
7$2,451,112$2,023,225.58$12,820$4,101.38+$2.44MDUKH
8$25,802,469$23,179,779.61$17,673$6,826.70+$25.78MDUKH
9$483,701,953$456,093,310.87$27,543$12,591.86+$483.67MDUKH
10$16,499,022,717$15,981,461,627.54$49,560$26,258.71+$16498.97MDUKH

DUKH vs PFE: Complete Analysis 2026

DUKHStock

DUKH invests in unaffiliated high-yield fixed income ETFs using a proprietary trend-following strategy. The underlying ETFs, which could be passively or actively managed, may invest in government and corporate high-yield bonds of any maturity from around the world. The fund expects to allocate nearly all its assets to these ETFs. In selecting investments, the fund adviser determines buy and sell signals by calculating the upper and lower bands of the short-term exponential moving averages. A buy signal is initiated when a potential uptrend in a candidate ETF is detected. To limit drawdowns of the overall fund, an ETF is sold when a sell signal is identified. In the absence of uptrends, the fund may reinvest in US Treasury ETFs and/or cash equivalents. It applies the same trend-following strategy for Treasury ETFs. The fund is not limited by any constraints on the number or type of underlying ETFs it may invest in. The adviser periodically reviews and adjusts the allocation of the fund.

Full DUKH Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this DUKH vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DUKH vs SCHDDUKH vs JEPIDUKH vs ODUKH vs KODUKH vs MAINDUKH vs JNJDUKH vs MRKDUKH vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.